{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:08:52Z","timestamp":1780484932200,"version":"3.54.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DK","award":["113592"],"award-info":[{"award-number":["113592"]}]},{"name":"AA","award":["024206"],"award-info":[{"award-number":["024206"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a severe form of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), traditionally diagnosed via invasive biopsy, underscoring the need for non-invasive alternatives. This study identifies biologically relevant extracellular vesicle (EV) protein signatures associated with MASH using patient serum, primary human hepatocytes (PHH), and human liver organoids (HLO). These complementary models capture distinct aspects of disease progression-circulating EV profiles in patients, hepatic cellular responses in PHH, and multicellular interactions in HLO-providing a comprehensive view of MASH pathophysiology. Using aptamer-based technology, we assayed 6596 proteins from 38 individuals with histological confirmed MASLD and in vitro models. EVs were characterized using nano-flow cytometry, ExoView, and high-resolution microscopy (ONI), with liver-specific markers confirming their origin. Key proteins, including SLC27A5, HP, and CXCL7, were elevated in patient samples, while PHH and HLO models exhibited upregulation of ASGPR1, HP, and CXCL7 under MASH conditions. Proteomic analysis revealed shared pathways across models, with machine learning models achieving AUROC values of 0.97, supporting the diagnostic potential of these protein signatures. This integrative approach advances MASH biomarker discovery by linking localized liver dysfunction with systemic disease mechanisms. These findings highlight clinically relevant EV protein signatures that support the development of non-invasive diagnostics and personalized treatment strategies, including prediction of outcomes for bariatric surgery patients.<\/jats:p>","DOI":"10.1038\/s41598-026-40490-x","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:39:16Z","timestamp":1780483156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures"],"prefix":"10.1038","volume":"16","author":[{"given":"Aleksandra","family":"Leszczynska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stoess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Reca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Kyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Povero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Crafts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel E.","family":"Feldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"40490_CR1","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","volume":"36","author":"MA Tincopa","year":"2024","unstructured":"Tincopa, M. A., Anstee, Q. M. & Loomba, R. New and emerging treatments for metabolic dysfunction-associated steatohepatitis. Cell Metab. 36, 912\u2013926. https:\/\/doi.org\/10.1016\/j.cmet.2024.03.011 (2024).","journal-title":"Cell Metab."},{"key":"40490_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. et al. Advancing the global public health agenda for NAFLD: A consensus statement. Nat. Rev. Gastroenterol. Hepatol. 19, 60\u201378. https:\/\/doi.org\/10.1038\/s41575-021-00523-4 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"40490_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","volume":"20","author":"Y Sumida","year":"2014","unstructured":"Sumida, Y., Nakajima, A. & Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 475\u2013485. https:\/\/doi.org\/10.3748\/wjg.v20.i2.475 (2014).","journal-title":"World J. Gastroenterol."},{"key":"40490_CR4","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264-1281 e1264. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036 (2019).","journal-title":"Gastroenterology"},{"key":"40490_CR5","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","volume":"54","author":"G Sveinbjornsson","year":"2022","unstructured":"Sveinbjornsson, G. et al. Multiomics study of nonalcoholic fatty liver disease. Nat. Genet. 54, 1652\u20131663. https:\/\/doi.org\/10.1038\/s41588-022-01199-5 (2022).","journal-title":"Nat. Genet."},{"key":"40490_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/CLD.0000000000000066","volume":"22","author":"KM Tun","year":"2023","unstructured":"Tun, K. M., Noureddin, N. & Noureddin, M. Noninvasive tests in the evaluation of nonalcoholic fatty liver disease: A review. Clin. Liver Dis. (Hoboken) 22, 103\u2013112. https:\/\/doi.org\/10.1097\/CLD.0000000000000066 (2023).","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"40490_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48956-0","volume":"15","author":"L Verschuren","year":"2024","unstructured":"Verschuren, L. et al. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. Nat. Commun. 15, 4564. https:\/\/doi.org\/10.1038\/s41467-024-48956-0 (2024).","journal-title":"Nat. Commun."},{"key":"40490_CR8","doi-asserted-by":"publisher","first-page":"7763","DOI":"10.1021\/acs.analchem.0c04850","volume":"93","author":"MT Odenkirk","year":"2021","unstructured":"Odenkirk, M. T., Reif, D. M. & Baker, E. S. Multiomic big data analysis challenges: Increasing confidence in the interpretation of artificial intelligence assessments. Anal. Chem. 93, 7763\u20137773. https:\/\/doi.org\/10.1021\/acs.analchem.0c04850 (2021).","journal-title":"Anal. Chem."},{"key":"40490_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49986-4","volume":"15","author":"M Slobodyanyuk","year":"2024","unstructured":"Slobodyanyuk, M. et al. Directional integration and pathway enrichment analysis for multi-omics data. Nat. Commun. 15, 5690. https:\/\/doi.org\/10.1038\/s41467-024-49986-4 (2024).","journal-title":"Nat. Commun."},{"key":"40490_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","volume":"23","author":"JG Greener","year":"2022","unstructured":"Greener, J. G., Kandathil, S. M., Moffat, L. & Jones, D. T. A guide to machine learning for biologists. Nat. Rev. Mol. Cell Biol. 23, 40\u201355. https:\/\/doi.org\/10.1038\/s41580-021-00407-0 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"40490_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.cell.2018.05.015","volume":"173","author":"DM Camacho","year":"2018","unstructured":"Camacho, D. M., Collins, K. M., Powers, R. K., Costello, J. C. & Collins, J. J. Next-generation machine learning for biological networks. Cell 173, 1581\u20131592. https:\/\/doi.org\/10.1016\/j.cell.2018.05.015 (2018).","journal-title":"Cell"},{"key":"40490_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41568-024-00694-7","volume":"24","author":"R Perez-Lopez","year":"2024","unstructured":"Perez-Lopez, R., Ghaffari Laleh, N., Mahmood, F. & Kather, J. N. A guide to artificial intelligence for cancer researchers. Nat. Rev. Cancer 24, 427\u2013441. https:\/\/doi.org\/10.1038\/s41568-024-00694-7 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"40490_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41587-021-01145-6","volume":"40","author":"A Santos","year":"2022","unstructured":"Santos, A. et al. A knowledge graph to interpret clinical proteomics data. Nat. Biotechnol. 40, 692\u2013702. https:\/\/doi.org\/10.1038\/s41587-021-01145-6 (2022).","journal-title":"Nat. Biotechnol."},{"key":"40490_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-022-01850-y","volume":"28","author":"L Niu","year":"2022","unstructured":"Niu, L. et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat. Med. 28, 1277\u20131287. https:\/\/doi.org\/10.1038\/s41591-022-01850-y (2022).","journal-title":"Nat. Med."},{"key":"40490_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47899-w","volume":"15","author":"H Peng","year":"2024","unstructured":"Peng, H., Wang, H., Kong, W., Li, J. & Goh, W. W. B. Optimizing differential expression analysis for proteomics data via high-performing rules and ensemble inference. Nat. Commun. 15, 3922. https:\/\/doi.org\/10.1038\/s41467-024-47899-w (2024).","journal-title":"Nat. Commun."},{"key":"40490_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102230","volume":"47","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Li, X. & Xiong, X. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers. Clin. Res. Hepatol. Gastroenterol. 47, 102230. https:\/\/doi.org\/10.1016\/j.clinre.2023.102230 (2023).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"40490_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101278","volume":"29","author":"M Jimenez Ramos","year":"2024","unstructured":"Jimenez Ramos, M., Kendall, T. J., Drozdov, I. & Fallowfield, J. A. A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease. Ann. Hepatol. 29, 101278. https:\/\/doi.org\/10.1016\/j.aohep.2023.101278 (2024).","journal-title":"Ann. Hepatol."},{"key":"40490_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750. https:\/\/doi.org\/10.1080\/20013078.2018.1535750 (2018).","journal-title":"J. Extracell. Vesicles"},{"key":"40490_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/hep4.1556","volume":"4","author":"D Povero","year":"2020","unstructured":"Povero, D. et al. Characterization and proteome of circulating extracellular vesicles as potential biomarkers for NASH. Hepatol. Commun. 4, 1263\u20131278. https:\/\/doi.org\/10.1002\/hep4.1556 (2020).","journal-title":"Hepatol. Commun."},{"key":"40490_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713326","author":"NA Garcia","year":"2023","unstructured":"Garcia, N. A., Mellergaard, M., Gonzalez-King, H., Salomon, C. & Handberg, A. Comprehensive strategy for identifying extracellular vesicle surface proteins as biomarkers for non-alcoholic fatty liver disease. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241713326 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"40490_CR21","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3892\/or.2016.5312","volume":"37","author":"Q Guo","year":"2017","unstructured":"Guo, Q., Jian, Z., Jia, B. & Chang, L. CXCL7 promotes proliferation and invasion of cholangiocarcinoma cells. Oncol. Rep. 37, 1114\u20131122. https:\/\/doi.org\/10.3892\/or.2016.5312 (2017).","journal-title":"Oncol. Rep."},{"key":"40490_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168846","author":"M Zajkowska","year":"2022","unstructured":"Zajkowska, M. & Mroczko, B. Chemokines in primary liver cancer. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23168846 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"40490_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0471-0","volume":"16","author":"Y Maneerat","year":"2017","unstructured":"Maneerat, Y., Prasongsukarn, K., Benjathummarak, S. & Dechkhajorn, W. PPBP and DEFA1\/DEFA3 genes in hyperlipidaemia as feasible synergistic inflammatory biomarkers for coronary heart disease. Lipids Health Dis. 16, 80. https:\/\/doi.org\/10.1186\/s12944-017-0471-0 (2017).","journal-title":"Lipids Health Dis."},{"key":"40490_CR24","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v5.31209","volume":"5","author":"JL Welton","year":"2016","unstructured":"Welton, J. L. et al. Proteomics analysis of vesicles isolated from plasma and urine of prostate cancer patients using a multiplex, aptamer-based protein array. J. Extracell. Vesicles 5, 31209. https:\/\/doi.org\/10.3402\/jev.v5.31209 (2016).","journal-title":"J. Extracell. Vesicles"},{"key":"40490_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225363","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. & Zhan, F. Type 2 cystatins and their roles in the regulation of human immune response and cancer progression. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers15225363 (2023).","journal-title":"Cancers (Basel)"},{"key":"40490_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101120","volume":"21","author":"T Zhou","year":"2019","unstructured":"Zhou, T., Chang, L., Luo, Y., Zhou, Y. & Zhang, J. Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy. Redox Biol. 21, 101120. https:\/\/doi.org\/10.1016\/j.redox.2019.101120 (2019).","journal-title":"Redox Biol."},{"key":"40490_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000171362","volume":"10","author":"S Moller","year":"1992","unstructured":"Moller, S. & Becker, U. Insulin-like growth factor 1 and growth hormone in chronic liver disease. Dig. Dis. 10, 239\u2013248. https:\/\/doi.org\/10.1159\/000171362 (1992).","journal-title":"Dig. Dis."},{"key":"40490_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s10875-022-01376-5","volume":"43","author":"CB Korol","year":"2023","unstructured":"Korol, C. B. et al. Fulminant viral hepatitis in two siblings with inherited IL-10RB deficiency. J. Clin. Immunol. 43, 406\u2013420. https:\/\/doi.org\/10.1007\/s10875-022-01376-5 (2023).","journal-title":"J. Clin. Immunol."},{"key":"40490_CR29","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1021\/acs.jproteome.0c00270","volume":"19","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Glycopeptide biomarkers in serum haptoglobin for hepatocellular carcinoma detection in patients with nonalcoholic steatohepatitis. J. Proteome Res. 19, 3452\u20133466. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00270 (2020).","journal-title":"J. Proteome Res."},{"key":"40490_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J. Hepatol. 78, 693\u2013703. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.029 (2023).","journal-title":"J. Hepatol."},{"key":"40490_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJM199702273360907","volume":"336","author":"D Le Roith","year":"1997","unstructured":"Le Roith, D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N. Engl. J. Med. 336, 633\u2013640. https:\/\/doi.org\/10.1056\/NEJM199702273360907 (1997).","journal-title":"N. Engl. J. Med."},{"key":"40490_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ecl.2006.11.005","volume":"36","author":"JO Jorgensen","year":"2007","unstructured":"Jorgensen, J. O., Moller, L., Krag, M., Billestrup, N. & Christiansen, J. S. Effects of growth hormone on glucose and fat metabolism in human subjects. Endocrinol. Metab. Clin. North Am. 36, 75\u201387. https:\/\/doi.org\/10.1016\/j.ecl.2006.11.005 (2007).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"40490_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01735-1","volume":"9","author":"MA Kumar","year":"2024","unstructured":"Kumar, M. A. et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct. Target. Ther. 9, 27. https:\/\/doi.org\/10.1038\/s41392-024-01735-1 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"40490_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s12072-007-9007-4","volume":"1","author":"T Ichikawa","year":"2007","unstructured":"Ichikawa, T. et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol. Int. 1, 287\u2013294. https:\/\/doi.org\/10.1007\/s12072-007-9007-4 (2007).","journal-title":"Hepatol. Int."},{"key":"40490_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101243","volume":"51","author":"P Liu","year":"2021","unstructured":"Liu, P. et al. Non-canonical NRF2 activation promotes a pro-diabetic shift in hepatic glucose metabolism. Mol. Metab. 51, 101243. https:\/\/doi.org\/10.1016\/j.molmet.2021.101243 (2021).","journal-title":"Mol. Metab."},{"key":"40490_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01200-4","volume":"8","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Arginase: Shedding light on the mechanisms and opportunities in cardiovascular diseases. Cell Death Discov. 8, 413. https:\/\/doi.org\/10.1038\/s41420-022-01200-4 (2022).","journal-title":"Cell Death Discov."},{"key":"40490_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.matbio.2017.11.011","volume":"68","author":"M Roderfeld","year":"2018","unstructured":"Roderfeld, M. Matrix metalloproteinase functions in hepatic injury and fibrosis. Matrix Biol. 68, 452\u2013462. https:\/\/doi.org\/10.1016\/j.matbio.2017.11.011 (2018).","journal-title":"Matrix Biol."},{"key":"40490_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/hep.28379","volume":"63","author":"D Dibra","year":"2016","unstructured":"Dibra, D. et al. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology 63, 1000\u20131012. https:\/\/doi.org\/10.1002\/hep.28379 (2016).","journal-title":"Hepatology"},{"key":"40490_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7726058","volume":"2021","author":"H Guan","year":"2021","unstructured":"Guan, H., Guo, Y., Zhu, L., Jiao, Y. & Liu, X. Peroxisome deficiency dysregulates fatty acid oxidization and exacerbates lipotoxicity in beta cells. Oxid. Med. Cell. Longev. 2021, 7726058. https:\/\/doi.org\/10.1155\/2021\/7726058 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"key":"40490_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000528847","volume":"3","author":"J Rubin","year":"2023","unstructured":"Rubin, J., Mariani, L., Smith, A. & Zee, J. Ridge regression for functional form identification of continuous predictors of clinical outcomes in glomerular disease. Glomerular Dis. 3, 47\u201355. https:\/\/doi.org\/10.1159\/000528847 (2023).","journal-title":"Glomerular Dis."},{"key":"40490_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/e23010018","author":"P Linardatos","year":"2020","unstructured":"Linardatos, P., Papastefanopoulos, V. & Kotsiantis, S. Explainable AI: A review of machine learning interpretability methods. Entropy https:\/\/doi.org\/10.3390\/e23010018 (2020).","journal-title":"Entropy"},{"key":"40490_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56489-1","volume":"14","author":"ME AlMansoori","year":"2024","unstructured":"AlMansoori, M. E., Jemimah, S., Abuhantash, F. & AlShehhi, A. Predicting early Alzheimer\u2019s with blood biomarkers and clinical features. Sci. Rep. 14, 6039. https:\/\/doi.org\/10.1038\/s41598-024-56489-1 (2024).","journal-title":"Sci. Rep."},{"key":"40490_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41416-021-01610-8","volume":"126","author":"M Ramirez-Garrastacho","year":"2022","unstructured":"Ramirez-Garrastacho, M. et al. Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: A decade of research. Br. J. Cancer 126, 331\u2013350. https:\/\/doi.org\/10.1038\/s41416-021-01610-8 (2022).","journal-title":"Br. J. Cancer"},{"key":"40490_CR44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50176","volume":"15","author":"KK Adhit","year":"2023","unstructured":"Adhit, K. K., Wanjari, A., Menon, S. & K, S. Liquid biopsy: An evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. Cureus 15, e50176. https:\/\/doi.org\/10.7759\/cureus.50176 (2023).","journal-title":"Cureus"},{"key":"40490_CR45","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.jhep.2019.01.030","volume":"70","author":"A Eguchi","year":"2019","unstructured":"Eguchi, A., Kostallari, E., Feldstein, A. E. & Shah, V. H. Extracellular vesicles, the liquid biopsy of the future. J. Hepatol. 70, 1292\u20131294. https:\/\/doi.org\/10.1016\/j.jhep.2019.01.030 (2019).","journal-title":"J. Hepatol."},{"key":"40490_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/hep.28838","volume":"65","author":"A Eguchi","year":"2017","unstructured":"Eguchi, A. et al. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology 65, 475\u2013490. https:\/\/doi.org\/10.1002\/hep.28838 (2017).","journal-title":"Hepatology"},{"key":"40490_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40328-4","volume":"14","author":"J Boursier","year":"2023","unstructured":"Boursier, J. et al. Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests. Nat. Commun. 14, 5219. https:\/\/doi.org\/10.1038\/s41467-023-40328-4 (2023).","journal-title":"Nat. Commun."},{"key":"40490_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103365","volume":"67","author":"E Zhou","year":"2021","unstructured":"Zhou, E. et al. Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy. EBioMedicine 67, 103365. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103365 (2021).","journal-title":"EBioMedicine"},{"key":"40490_CR49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/HEP.0000000000000300","volume":"78","author":"YJ Abozaid","year":"2023","unstructured":"Abozaid, Y. J. et al. Plasma proteomic signature of fatty liver disease: The Rotterdam Study. Hepatology 78, 284\u2013294. https:\/\/doi.org\/10.1097\/HEP.0000000000000300 (2023).","journal-title":"Hepatology"},{"key":"40490_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204673","author":"L Niu","year":"2021","unstructured":"Niu, L. et al. Defining NASH from a multi-omics systems biology perspective. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm10204673 (2021).","journal-title":"J. Clin. Med."},{"key":"40490_CR51","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep4.1670","volume":"5","author":"Y Luo","year":"2021","unstructured":"Luo, Y. et al. SOMAscan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH. Hepatol. Commun. 5, 760\u2013773. https:\/\/doi.org\/10.1002\/hep4.1670 (2021).","journal-title":"Hepatol. Commun."},{"key":"40490_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100661","volume":"5","author":"EA Brown","year":"2023","unstructured":"Brown, E. A. et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 5, 100661. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100661 (2023).","journal-title":"JHEP Rep."},{"key":"40490_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2021.100149","volume":"12","author":"P Zarghamravanbakhsh","year":"2021","unstructured":"Zarghamravanbakhsh, P., Frenkel, M. & Poretsky, L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabol. Open 12, 100149. https:\/\/doi.org\/10.1016\/j.metop.2021.100149 (2021).","journal-title":"Metabol. Open"},{"key":"40490_CR54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby, T. & Gautier, E. L. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat. Rev. Immunol. 22, 429\u2013443. https:\/\/doi.org\/10.1038\/s41577-021-00639-3 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"40490_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100648","volume":"5","author":"TD Christensen","year":"2023","unstructured":"Christensen, T. D. et al. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer. JHEP Rep. 5, 100648. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100648 (2023).","journal-title":"JHEP Rep."},{"key":"40490_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55438-2","volume":"14","author":"R Kostadinova","year":"2024","unstructured":"Kostadinova, R. et al. Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model. Sci. Rep. 14, 5885. https:\/\/doi.org\/10.1038\/s41598-024-55438-2 (2024).","journal-title":"Sci. Rep."},{"key":"40490_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186097","volume":"14","author":"N Stiglund","year":"2023","unstructured":"Stiglund, N., Hagstrom, H., Stal, P., Cornillet, M. & Bjorkstrom, N. K. Dysregulated peripheral proteome reveals NASH-specific signatures identifying patient subgroups with distinct liver biology. Front. Immunol. 14, 1186097. https:\/\/doi.org\/10.3389\/fimmu.2023.1186097 (2023).","journal-title":"Front. Immunol."},{"key":"40490_CR58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez, E. & Chalasani, N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J. Hepatol. 68, 305\u2013315. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.013 (2018).","journal-title":"J. Hepatol."},{"key":"40490_CR59","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(19)32998-8","volume":"395","author":"OJ Skrede","year":"2020","unstructured":"Skrede, O. J. et al. Deep learning for prediction of colorectal cancer outcome: A discovery and validation study. Lancet 395, 350\u2013360. https:\/\/doi.org\/10.1016\/S0140-6736(19)32998-8 (2020).","journal-title":"Lancet"},{"key":"40490_CR60","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3350\/cmh.2021.0394","volume":"28","author":"SH Lee","year":"2022","unstructured":"Lee, S. H. & Jang, H. J. Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology. Clin. Mol. Hepatol. 28, 754\u2013772. https:\/\/doi.org\/10.3350\/cmh.2021.0394 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"40490_CR61","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cels.2021.06.006","volume":"12","author":"M Mann","year":"2021","unstructured":"Mann, M., Kumar, C., Zeng, W. F. & Strauss, M. T. Artificial intelligence for proteomics and biomarker discovery. Cell Syst. 12, 759\u2013770. https:\/\/doi.org\/10.1016\/j.cels.2021.06.006 (2021).","journal-title":"Cell Syst."},{"key":"40490_CR62","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3978\/j.issn.2072-1439.2015.04.61","volume":"7","author":"A Pasini","year":"2015","unstructured":"Pasini, A. Artificial neural networks for small dataset analysis. J. Thorac. Dis. 7, 953\u2013960. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2015.04.61 (2015).","journal-title":"J. Thorac. Dis."},{"key":"40490_CR63","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): A comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714\u2013725. https:\/\/doi.org\/10.1016\/S2468-1253(23)00017-1 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"40490_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-1-7","volume":"1","author":"SG Pearce","year":"2013","unstructured":"Pearce, S. G., Thosani, N. C. & Pan, J. J. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark. Res. 1, 7. https:\/\/doi.org\/10.1186\/2050-7771-1-7 (2013).","journal-title":"Biomark. Res."},{"key":"40490_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13111115","author":"GE Gilca-Blanariu","year":"2023","unstructured":"Gilca-Blanariu, G. E. et al. Advances in noninvasive biomarkers for nonalcoholic fatty liver disease. Metabolites https:\/\/doi.org\/10.3390\/metabo13111115 (2023).","journal-title":"Metabolites"},{"key":"40490_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01383-7","volume":"21","author":"C Caussy","year":"2021","unstructured":"Caussy, C., Aubin, A. & Loomba, R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr. Diab. Rep. 21, 15. https:\/\/doi.org\/10.1007\/s11892-021-01383-7 (2021).","journal-title":"Curr. Diab. Rep."},{"key":"40490_CR67","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho, E. et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis. Gut 72, 2138\u20132148. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110 (2023).","journal-title":"Gut"},{"key":"40490_CR68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera, V. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 78, 471\u2013478. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.010 (2023).","journal-title":"J. Hepatol."},{"key":"40490_CR69","doi-asserted-by":"publisher","DOI":"10.21037\/dmr-21-87","author":"KL Poulsen","year":"2022","unstructured":"Poulsen, K. L., Cajigas-Du Ross, C. K., Chaney, J. K. & Nagy, L. E. Role of the chemokine system in liver fibrosis: A narrative review. Dig. Med. Res. https:\/\/doi.org\/10.21037\/dmr-21-87 (2022).","journal-title":"Dig. Med. Res."},{"key":"40490_CR70","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00109-015-1319-6","volume":"93","author":"L Basset","year":"2015","unstructured":"Basset, L. et al. Interleukin-27 and IFNgamma regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. J. Mol. Med. (Berl.) 93, 1355\u20131367. https:\/\/doi.org\/10.1007\/s00109-015-1319-6 (2015).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"40490_CR71","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.28331","volume":"63","author":"P Starlinger","year":"2016","unstructured":"Starlinger, P. et al. The profile of platelet alpha-granule released molecules affects postoperative liver regeneration. Hepatology 63, 1675\u20131688. https:\/\/doi.org\/10.1002\/hep.28331 (2016).","journal-title":"Hepatology"},{"key":"40490_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.914730","volume":"13","author":"Q Wu","year":"2022","unstructured":"Wu, Q., Tu, H. & Li, J. Multifaceted roles of chemokine C-X-C motif ligand 7 in inflammatory diseases and cancer. Front. Pharmacol. 13, 914730. https:\/\/doi.org\/10.3389\/fphar.2022.914730 (2022).","journal-title":"Front. Pharmacol."},{"key":"40490_CR73","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/ATVBAHA.108.169417","volume":"28","author":"CA Gleissner","year":"2008","unstructured":"Gleissner, C. A., von Hundelshausen, P. & Ley, K. Platelet chemokines in vascular disease. Arterioscler. Thromb. Vasc. Biol. 28, 1920\u20131927. https:\/\/doi.org\/10.1161\/ATVBAHA.108.169417 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"40490_CR74","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1134\/S1990750821030069","volume":"15","author":"SN Naryzny","year":"2021","unstructured":"Naryzny, S. N. & Legina, O. K. Haptoglobin as a biomarker. Biochemistry (Mosc.) Suppl. Ser. B Biomed. Chem. 15, 184\u2013198. https:\/\/doi.org\/10.1134\/S1990750821030069 (2021).","journal-title":"Biochemistry (Mosc.) Suppl. Ser. B Biomed. Chem."},{"key":"40490_CR75","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ajh.23623","volume":"89","author":"AW Shih","year":"2014","unstructured":"Shih, A. W., McFarlane, A. & Verhovsek, M. Haptoglobin testing in hemolysis: Measurement and interpretation. Am. J. Hematol. 89, 443\u2013447. https:\/\/doi.org\/10.1002\/ajh.23623 (2014).","journal-title":"Am. J. Hematol."},{"key":"40490_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066328","volume":"8","author":"Y Kamada","year":"2013","unstructured":"Kamada, Y. et al. Serum fucosylated haptoglobin as a novel diagnostic biomarker for predicting hepatocyte ballooning and nonalcoholic steatohepatitis. PLoS ONE 8, e66328. https:\/\/doi.org\/10.1371\/journal.pone.0066328 (2013).","journal-title":"PLoS ONE"},{"key":"40490_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279416","volume":"17","author":"K Shirai","year":"2022","unstructured":"Shirai, K. et al. Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. PLoS ONE 17, e0279416. https:\/\/doi.org\/10.1371\/journal.pone.0279416 (2022).","journal-title":"PLoS ONE"},{"key":"40490_CR78","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 155, 1140\u20131153. https:\/\/doi.org\/10.1053\/j.gastro.2018.07.006 (2018).","journal-title":"Gastroenterology"},{"key":"40490_CR79","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125652","author":"D Povero","year":"2019","unstructured":"Povero, D. et al. Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.125652 (2019).","journal-title":"JCI Insight"},{"key":"40490_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.49","volume":"3","author":"JC Rohloff","year":"2014","unstructured":"Rohloff, J. C. et al. Nucleic acid ligands with protein-like side chains: Modified aptamers and their use as diagnostic and therapeutic agents. Mol. Ther. Nucl. Acids 3, e201. https:\/\/doi.org\/10.1038\/mtna.2014.49 (2014).","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"40490_CR81","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1073\/pnas.94.1.59","volume":"94","author":"L Gold","year":"1997","unstructured":"Gold, L. et al. From oligonucleotide shapes to genomic SELEX: Novel biological regulatory loops. Proc. Natl. Acad. Sci. U.S.A. 94, 59\u201364. https:\/\/doi.org\/10.1073\/pnas.94.1.59 (1997).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40490-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40490-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:39:18Z","timestamp":1780483158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40490-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40490"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40490-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17147"}}